Remus Pharmaceuticals Ratios

Remus Pharmaceuticals Ltd Ratios

The Remus Pharmaceuticals Ltd Ratios page provides a complete fundamental analysis of Remus Pharmaceuticals Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Remus Pharmaceuticals Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Remus Pharmaceuticals Ltd (NSE: REMUS, BSE: 78788) is currently trading at ₹746.90, with a market capitalization of ₹8.43B. As a major player in the Health technology sector and Pharmaceuticals: major industry, Remus Pharmaceuticals Ltd remains a key stock for fundamental analysis using Remus Pharmaceuticals Ltd Ratios.

Remus Pharmaceuticals Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Remus Pharmaceuticals Ltd P/E ratio currently stands at 0, making it one of the most tracked metrics in Remus Pharmaceuticals Ltd Ratios.

Historically, the Remus Pharmaceuticals Ltd P/E ratio has shown strong fluctuations:

The decline in Remus Pharmaceuticals Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Remus Pharmaceuticals Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 0.

Historical P/B trend:

Remus Pharmaceuticals Ltd shows reasonable valuation compared to its asset base.

Price to Sales Ratio (P/S)

The Remus Pharmaceuticals Ltd P/S ratio currently stands at 0, an important part of Remus Pharmaceuticals Ltd Ratios for revenue valuation.

Historical P/S ratio:

A stable or declining Remus Pharmaceuticals Ltd P/S ratio indicates cautious market sentiment.

Remus Pharmaceuticals Ltd Price to Cash Flow Ratio (P/CF)

The Remus Pharmaceuticals Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 0.

Historical Remus Pharmaceuticals Ltd Price to Cash Flow Ratio:

The declining Remus Pharmaceuticals Ltd Price to Cash Flow Ratio suggests improving cash flow strength.

Remus Pharmaceuticals Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Remus Pharmaceuticals Ltd EV currently stands at ₹0, representing the total company valuation including debt.

Historical EV trend:

Remus Pharmaceuticals Ltd enterprise value consolidation suggests stable valuation.

EV/EBITDA Ratio

The Remus Pharmaceuticals Ltd EV/EBITDA ratio is currently 0, a key metric in Remus Pharmaceuticals Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

Stable Remus Pharmaceuticals Ltd EV/EBITDA indicates balanced valuation.

Remus Pharmaceuticals Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Remus Pharmaceuticals Ltd D/E ratio is currently 0, reflecting leverage and financial stability.

Historical D/E:

Remus Pharmaceuticals Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Remus Pharmaceuticals Ltd ROE currently stands at 0%, showing profitability and capital efficiency.

Historical ROE:

Declining ROE indicates pressure on profitability.

Remus Pharmaceuticals Ltd Ratios Analysis Summary

The Remus Pharmaceuticals Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Remus Pharmaceuticals Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Remus Pharmaceuticals Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.